US Patent

US7772178 — Pharmaceutical formulations and methods of treatment using the same

Method of Use · Assigned to Schering Corp · Expires 2027-11-11 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical formulations containing specific compounds and surfactants, suitable for use in single unit dosages.

USPTO Abstract

Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.

Drugs covered by this patent

Victrelis (BOCEPREVIR) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1128`	—	Victrelis

Patent Metadata

Patent number: US7772178
Jurisdiction: US
Classification: Method of Use
Expires: 2027-11-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Schering Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.